Pharvaris To Present New Data On Hereditary Angioedema Treatment At Upcoming Conferences

Benzinga · 10/16 10:52

Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows:

 

American College of Allergy, Asthma, & Immunology's Annual Scientific Meeting (ACAAI), Boston, October 24-28, 2024. Seven abstracts have been accepted for e-Poster presentation:

  • Poster: Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: CHAPTER-1 Open-Label Extension Study

    Speaker: John Anderson, M.D.

    Format: e-Poster (R102)

    Date, Time: Friday, Oct. 25, 2:00-2:15 p.m. EDT

    Location: Monitor 21, Exhibit Hall A
  • Poster: Long-Term Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant: RAPIDe-2 Extension Study Results

    Speaker: John Anderson, M.D.

    Format: e-Poster (R103)

    Date, Time: Friday, Oct. 25, 2:15-2:30 p.m. EDT

    Location: Monitor 21, Exhibit Hall A
  • Poster: Development Of A Novel Kinin Biomarker Assay For Characterization Of Bradykinin-Mediated Disorders

    Speaker: Evangelia Pardali, Ph.D.

    Format: e-Poster (R088)

    Date, Time: Friday, Oct. 25, 2:30-2:45 p.m. EDT

    Location: Monitor 20, Exhibit Hall A
  • Poster: Development of a HMWK Capillary Immunoblotting Assay for Characterization of Bradykinin-Mediated Disorders

    Speaker: Evangelia Pardali, Ph.D.

    Format: e-Poster (R090)

    Date, Time: Friday, Oct. 25, 3:00-3:15 p.m. EDT

    Location: Monitor 20, Exhibit Hall A
  • Poster: The Bradykinin Challenge Model In Non-Human Primates Successfully Predicted Efficacious Doses of Deucrictibant in Humans

    Speaker: Juan Bravo, Ph.D.

    Format: e-Poster (R112)

    Date, Time: Friday, Oct. 25, 4:30-4:45 p.m. EDT

    Location: Monitor 21, Exhibit Hall A
  • Poster: CHAPTER-1 Phase 2 Trial of Oral Bradykinin B2 Receptor Antagonist Deucrictibant for Hereditary Angioedema Prophylaxis

    Speaker: H. James Wedner, M.D.

    Format: e-Poster (R100)

    Date, time: Friday, Oct. 25, 5:30-5:45 p.m. EDT

    Location: Monitor 20, Exhibit Hall A
  • Poster: Prophylactic Treatment With Oral Deucrictibant Improves Hereditary Angioedema Disease Control and Health-Related Quality of Life

    Speaker: H. James Wedner, M.D.

    Format: e-Poster (R101)

    Date, Time: Friday, Oct. 25, 5:45-6:00 p.m. EDT

    Location: Monitor 20, Exhibit Hall A

     

Canadian Society of Allergy and Clinical Immunology (CSACI), Banff, Alberta, Canada, November 6-9, 2024. Three abstracts have been accepted for poster presentation.

  • Poster: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of HAE Attacks: Results of CHAPTER-1 Phase 2 Trial

    Speaker: William H. Yang, M.D., FRCPC, FAAAAI

    Format: Poster

    Date, Time: Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)
  • Poster: Long-term safety and efficacy of oral deucrictibant, a bradykinin B2 receptor antagonist, for prophylaxis in HAE: CHAPTER-1 extension study results

    Speaker: William H. Yang, M.D., FRCPC, FAAAAI

    Format: Poster

    Date, Time: Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)
  • Poster: Long-term efficacy and safety of oral bradykinin B2 receptor antagonist deucrictibant in treatment of HAE attacks: RAPIDe-2 extension study results 

    Speaker: Hugo Chapdelaine, M.D., FRCPC

    Format: Poster

    Date, Time: Thursday, Nov. 7, 12:30-1:00 p.m. MST (2:30-3:00 p.m. EST) and Friday, Nov. 8, 1:30-2:00 p.m. MST (3:30-4:00 p.m. EST)

Japanese Society of Allergology (JSA), Kyoto, Japan, October 18-20, 2024. One abstract has been accepted for oral presentation.

  • Presentation: Efficacy and safety of oral deucrictibant IR capsule in HAE: RAPIDe-3 phase 3 trial design

    Speaker: Prof. Michihiro Hide, M.D., Ph.D.

    Format: Oral Presentation

    Date, Time: Sunday, Oct. 20, 13:30-14:45 JST (12:30 -1:45 a.m. EDT)